BACKGROUND: Cross-cultural studies have long suggested that the high incidence of breast cancer in developed Western countries may be linked to the high prevalence of obesity and to high total energy intake. Recent studies show that hyperinsulinemia, increased concentration of insulin-like growth factor 1 and greater abdominal fat accumulation are markers of high risk for breast cancer. Increased serum concentrations of free estradiol and free testosterone are similar risk markers and are frequent concomitants of hyperinsulinemia. MECHANISMS: The mechanism by which such metabolic ± endocrine abnormality may promote mammary carcinogenesis is uncertain, but its effect is likely to predominate in the years approaching the menopause when obesity is common among Western women. In obese subjects, enlargement of adipose deposits is known to produce an excess of free fatty acids and tumor necrosis factor alpha, both of which may be involved in the pathogenesis of insulin resistance. In middle-aged women, the concomitants of hyperinsulinemia may activate invasive and proliferative activity in preneoplastic mammary lesions such as in situ duct carcinoma of the comedo type. This will enhance the risk of progression to invasive breast cancer, which is likely to manifest clinically mainly after the menopause. CONCLUSION: Weight reduction combined with a program of regular physical exercise has been shown to reduce both estrogen and insulin concentrations in obese women and such a regimen might be tested in clinical trials for an effect on breast cancer risk in obese women. Intervention is best begun around the age of 45 y, this being the age when in situ duct carcinoma would normally begin to show evidence of spontaneous involution in women without clinical evidence of invasive breast cancer.
Introduction
Markers of higher risk differ between premenopausal and postmenopausal breast cancer. Early age at the onset of menarche, delayed ®rst live birth and shorter duration of lactation are markers of increased risk in the etiology of premenopausal breast cancer, but show little association with postmenopausal breast cancer. Epidemiological evidence suggests that obesity, high total energy intake and inadequate physical exercise are most clearly associated with the high breast cancer risk found in postmenopausal Western women. 1, 2 Recent prospective studies show that markers of increased breast cancer risk in older women include higher serum concentrations of free estradiol and free testosterone. 3 ± 9 As detailed in a later section, these changes are often associated with abdominal fat accumulation and hyperinsulinemia.
Populations at increased risk to postmenopausal breast cancer usually show a higher prevalence of cancer precursor lesions such as duct carcinoma in situ (DCIS). 10 In women of all races, pathological and mammographic studies show that a proportion of precursor lesions in the breast undergo spontaneous regression as estrogen levels decline in the years leading up to the menopause. During the same period however, other lesions are undergoing change to invasive cancer. The much higher incidence of postmenopausal breast cancer in women of developed Western countries compared with Asian women in general suggests that, in the years leading up to the menopause, the risk of progression to invasive cancer is greatly increased.
It is clear that a combination of high total energy intake and inadequate physical exercise allows genetically susceptible individuals to become obese. Increased metabolic activity in their enlarged adipose deposits releases an excess of free fatty acids and tumor necrosis factor alpha. 11 Both may be involved in the pathogenesis of hyperinsulinemic insulin resistance in genetically predisposed individuals as they become older. The following evidence suggests that mammary carcinogenesis may be promoted in obese middle-aged women as a result of synergistic activity between the concomitants of hyperinsulinemia and the increased estrogen concentrations derived from aro-matization in adipose tissue. Their combined effect may stimulate local molecular and biochemical activity which regulates the invasive potential of preneoplastic mammary lesions. 12 A healthy diet±exercise lifestyle that might decrease breast cancer risk has been proposed in children in order to avoid early onset of menarche, which is a well-recognized marker of increased risk of premenopausal breast cancer. Avoidance of obesity has also been advocated in postmenopausal women in order to reduce their risk of breast cancer. Avoidance of obesity has, however, not been advised in adult premenopausal women for this purpose because a higher body mass has not been related to increased risk of premenopausal breast cancer. A review of recent studies does, however, show that obesity in adult women before the menopause is associated with increased risk of postmenopausal breast cancer. 13 The review examines evidence that modi®cation in diet±exercise lifestyle, and reduction in obesity starting well before the menopause, might reduce breast cancer risk in postmenopausal women in developed Western countries. The hypothesis is based on clinical, epidemiological and biological studies on the progression of DCIS to invasive ductal cancer of the breast. It is also derived from examination of recently reported data on endocrine±metabolic markers of increased breast cancer risk.
Progression of intraductal carcinoma
The incidence of breast cancer in Western women is approximately ®ve times greater than that in Asian women and the difference is predominantly in its postmenopausal incidence. In Western populations, age-speci®c rates rise progressively even into old age, whereas in Asian countries they increase only up to the age of 50 y and then fall or remain static. 14 However, when low-risk ethnic groups migrate to the West, their incidence of postmenopausal breast cancer rises progressively in successive generations, suggesting that environmental rather than genetic factors are important in high risk.
The presence of DCIS in breast tissue has been associated with an up to 10-fold increase in breast cancer risk. Populations with a low breast cancer risk have a lower prevalence of DCIS in the general population than do those with a high risk, 10 suggesting a similar etiology for both conditions. However, cancerous breasts in low-risk populations manifest a higher incidence of DCIS than do those in high-risk population. 15 Taken together with the migrant data, it suggests that late-stage promoting factors are mainly responsible for high rates of postmenopausal breast cancer.
Currently, DCIS represents from 20% to 30% of mammographically-detected breast cancer and the peak incidence of DCIS is at the age of 45±50 y, followed by a steady decline. 16 Histopathologically also, the incidence of DCIS declines after the menopause and is associated with apoptosis, 17 evidence of programmed cell death, which regulates cell proliferation both in normal and malignant tissues. The degree of estrogen receptor (ER) expression peaks in mammary tissue at the DCIS stage 18 and it is assumed that apoptosis increases with withdrawal of endogenous ovarian steroids.
However, because hormone dependence is diminished in DCIS lesions of the comedo type, few of them are likely to regress at the menopause. Evidence of higher proliferative activity in ER negative DCIS lesions supports the hypothesis that progression towards invasive disease is paralleled by progressive loss of hormone dependence. 19 An attempt at breast cancer prevention by the use of anti-estrogen therapy is unlikely to inhibit the growth of such lesions. 20 Two recent randomized trials have shown a reduction in the incidence of primary breast cancer in postmenopausal women receiving long term anti-estrogen therapy. 21, 22 In both trials, the risk reduction was almost completely con®ned to ER positive tumors.
In breast specimens showing both DCIS and invasive cancer, there is strong correlation between the lesions in indices of proliferative activity (Ki67, Sphase, ploidy), steroid receptor status (ER, PgR), growth factor receptors (EGF receptor), oncogene and suppressor gene expression (HER-2neu, p53). 12 Loss of heterozygosity studies show no difference between the two tissues. 23 It has been concluded that DCIS cells already possess the genetic changes required for invasion and metastasis and also for hormonal anatomy. 24 It is mainly the in¯uence of epigenetic factors which triggers the ®nal invasion of the basement membrane. These factors are likely to control changes in expression of ER protein and proteolytic enzymes affecting cell migration, proliferation and angiogenic activity. 12 
Endocrine±metabolic markers of high risk
For many years inconsistent results were reported by studies assessing estrogen and androgen concentrations in breast cancer patients versus controls, but a consistent association has ®nally been con®rmed in a series of prospective studies. Of six prospective studies since 1990 which have examined the association with estrogen in postmenopausal cases 3 ± 7,25 all except one 25 report a signi®cant positive association between risk and estradiol concentrations. Of six prospective studies which examined the association with androgen, all have shown a positive association with testosterone concentrations. 4 ± 9 In four of these studies, 6 ± 9 the association was independent of estrogen concentrations, suggesting a direct effect on risk by testosterone independently of its conversion to estrogen in fat stores. The latest of these studies reports that the association with breast cancer risk was strongest for higher concentrations of bioavailable estradiol and for free testosterone. 7 This review suggests that the sex steroid abnormality associated with increased risk of postmenopausal breast cancer offers a clue to environmental or lifestyle etiological factors. Both in pre-and postmenopausal women, increased concentrations of both free estradiol and free testosterone are associated with abdominal fat accumulation and the latter has been shown to be associated with increased risk of breast cancer in multiple case-control studies, 26 ± 35 although not all agree. 36 The link between abdominal fat accumulation and hormonal change is likely to involve increased circulating levels of triglycerides and insulin, and decreased levels of sex hormonebinding globulin. 1 As a result, the androgen±estrogen ratio tends to be increased and this favors fat accumulation in the abdomen (android distribution) rather than in the femoral±gluteal region (gynoid distribution). Abdominal obesity is almost always associated with hyperinsulinemic insulin resistance whose manifestation depends on genetic susceptibility. In Western populations it is increasingly prevalent after the age of 35 y and is thought to be favoured by weight gain, high total energy intake and inadequate exercise. 37 Multiple case±control studies have shown that hyperinsulinemia also is associated with increased breast cancer risk, 38 ± 42 although one study is dissonant. 43 It is likely to increase the bioavailability of insulin-like growth factor 1 (IGF1) to target tissues by reducing the production of its binding proteins IGFBP1 and IGFBP3 in the liver. Recent studies have reported an association between increased serum concentrations of IGF1 andaor decreased concentrations of IGFBP3 on the one hand and breast cancer risk on the other, 42,44 ± 50 although one study is dissonant. 51 It is also relevant that a positive association has been reported between increased concentrations of IGF1 andaor decreased concentrations of IGFBP3, and an increased risk of cancers of the prostate, 52 lung 53 and colorectum. 54 Together with breast cancer, they comprise the most common forms of cancer in Western populations.
IGF1 is a peptide growth factor with autocrine and paracrine functions in many tissues including the breast, ovaries and adrenal cortex, and it also circulates as an endocrine factor which regulates tissue growth and fat deposition. Both estrogen and IGF1 are potent mitogens for most human breast cancer cell lines. Interaction between their receptors is likely to be involved in modulating the progression of mammary carcinogenesis. Thus, correlation between IGF1R and ER expression has been shown in breast cancer cell lines, mastectomy specimens and animal model studies. 55 In most breast cancer cell lines, IGF1 has been shown to stimulate ER expression, 56 while estrogen stimulates IGF1 receptor activity. 57 IGF1 bioactivity in mammary tissue is increased during progression from DCIS to invasive breast cancer. 58 The presence of IGF1 receptor protein is linked to mammary carcinogenesis, and prolonged overexpression of IGF1 receptor contributes to an estrogen-independent phenotype. 59 It is postulated in this review that overexpression of IGF1 receptor in DCIS lesions is favored by hyperinsulinemia, and its presence may stimulate local changes in molecular and biochemical regulatory pathways involved in progression to invasive cancer.
The mechanism by which IGF1 increases proliferative and invasive activity in mammary carcinogenesis is uncertain but a possible mediator is protein kinase C (PKC), a lipid-dependent cell membrane enzyme which is important in intracellular signalling. PKC levels are higher in breast cancer specimens than in normal breast tissue 60 and it has been suggested that PKC may mediate the effect of local growth factors in stimulating progression in premalignant cells. 61 It is reported that PKC activity in human breast cancer cell lines is increased by estradiol and inhibited by the anti-estrogen tamoxifen. 62 It is also relevant that in vitro exposure of breast cancer cells to essential fatty acids is reported to have altered the fatty acid composition of the cell membrane and resulted in dramatic increase in PKC activity when IGF1 was added. 63 Stimulation of PKC activity in breast cancer cell lines can increase their invasiveness 64 and decrease their expression of ER. 65 The anti-estrogen tamoxifen and the retinoid fenretinide are both currently under trial in breast cancer prevention and both have been shown to lower IGF1 concentrations during their administration.
Basis for selecting lifestyle changes
A trial of dietary fat reduction to 20% of total calories was initiated in 1994 in the USA in postmenopausal women. 66 Among its possible bene®ts it aims to reduce breast cancer risk, and its results may mature after 10 y. While it is widely assumed that dietary factors are prominent in the etiology of breast cancer, it is unclear whether a fat-rich diet or high energy intake are more important. The role of individual fatty acids, dietary ®ber and various vitamins is also under investigation.
Several studies have reported reduction of circulating estrogen concentrations after a reduced-fat diet both in pre-and postmenopausal women. 67, 68 Reduction of dietary fat almost inevitably increases the dietary ®ber content and this also has been shown to reduce estrogen concentrations in obese and nonAdiposity and postmenopausal breast cancer BA Stoll obese women. Studies in vegetarians generally show lower estradiol concentrations than in omniverous individuals both in pre and postmenopausal women. 69, 70 A study in premenopausal women has shown reduction of estrogen concentrations by wheat bran supplements (although not by oat or corn bran) without any change in dietary fat consumption. 71 The effect of either dietary fat or ®ber on estrogen concentrations may be involved in an effect by diet on breast cancer risk, but an effect on IGF1 concentrations may also play a part. Dietary restriction reduces mammary cancer incidence in rodent models and has been shown to decrease IGF1 concentrations. 72 High ®ber intake has been shown to improve insulin sensitivity 73 and in obese women this is generally associated with higher concentrations of sex hormonebinding globulin and reduced concentrations of free estradiol. Even a 3 week course of a high-®ber diet combined with exercise is reported to have normalized insulin concentrations in the majority of a group of patients with evidence of hyperinsulinemia. 74 Obesity in postmenopausal women has consistently been associated with higher breast cancer risk, and weight reduction has been shown to reduce circulating estrogen levels. 75 Weight reduction as protection against breast cancer risk has not been proposed in younger women mainly because some studies have suggested an association between obesity and decreased risk of premenopausal breast cancer. However, a recent study reports that the risk of premenopausal breast cancer is signi®cantly decreased only when the obesity occurs under the age of 18 y, while the effect of obesity after that age is minimal. 76 Moreover, a study of mainly postmenopausal cases of breast cancer strati®ed by patient's age at the onset of obesity, showed positive association with weight gain after the age of 30 y. 77 To explain these paradoxical observations, it is suggested that after the age of 30 y, accumulation of body fat in women is increasingly abdominal or visceral. The waistahip circumference ratio is inadequate as a measure of intra-abdominal fat as CAT or MRI scans have shown large visceral fat deposits in apparently lean women. 78 As noted above, abdominal fat accumulation is more important than increased body mass in an association with changes in sex steroid concentrations and with the risk of postmenopausal breast cancer.
The importance of physical exercise in relation to breast cancer risk is being increasingly recognised, and regular physical activity and exercise during adolescent and early adult life has been shown to reduce breast cancer risk in women. 79, 80 In the management of obesity, regular physical exercise may be as important as a reduction in total energy intake, and by decreasing abdominal and visceral fat stores it can reverse the development of hyperinsulinemic insulin resistance. 81 Improved insulin sensitivity and reduced abdominal fat deposits have resulted from long-term regular exercise in obese premenopausal women. 82 In addition, estrogen concentrations both in pre-and postmenopausal women can be reduced. In the case of young women, most of the evidence is derived from studies on athletes, but in the case of postmenopausal women, estrone levels have been shown to be lower in association with greater physical activity. 83 
Conclusion
Current approaches to breast cancer prevention include earlier diagnosis by mammographic screening, reduced dietary fat and increased ®ber intake, and trials of anti-estrogens such as tamoxifen or raloxifene, or retinoids such as fenretinide. The USA Women's Health Initiative Trial of dietary fat reduction 66 is restricted to postmenopausal women and any protective effect it might have against breast cancer would be in later postmenopausal years. Anti-estrogen trials aim to delay or inhibit the growth of occult or subclinical foci of breast cancer and an effect appears to be limited to ER positive breast cancer.
The years leading up to the menopause are a window for environmental risk factors which favor progression of DCIS to postmenopausal breast cancer, just as the years leading up to puberty are a window for those favoring the development of premenopausal breast cancer. 84 In women of all races after the age of 45 y, a proportion of DCIS lesions in women's breasts show mammographic and pathological evidence of regression related to the apoptosis which follows the gradual decline in estrogen concentrations. It is postulated that regression is opposed by epigenetic factors related to obesity, inadequate exercise and a high total dietary energy intake. In a subset of women, progression of DCIS lesions to invasive cancer is stimulated and in the majority of cases, manifests after the menopause.
It is suggested that metabolic markers of high breast cancer risk identifying such individuals include higher serum concentrations of insulin and IGF1 and also excessive abdominal fat accumulation. Dietary modi®cation, exercise regimens and reduction of obesity have all been shown to reduce the levels of these markers. It is postulated that a combination of all three regimens may counteract progression of precancerous lesions in breast tissue and are best begun around the age of 45 y.
The hypothesis can be tested by clinical trials of such interventions in premenopausal women showing evidence of excessive fat accumulation and high levels of fasting insulin. Serial assays of these markers and measurements of mammographic parenchymal density should be associated. Changes in genetic markers of malignant progression, such as p53 or HER-2neu, can be followed in nipple aspirates or ®ne needle or core aspirates of breast tissue. 11 Adiposity and postmenopausal breast cancer BA Stoll
